This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bilenker, J. H. Articles by O'Dwyer, P. J. Search for Related Content PubMed PubMed Citation Articles by Bilenker, J. H. Articles by O'Dwyer, P. J.

Phase I Trial of Combretastatin A-4 Phosphate with Carboplatin

¹ University of Pennsylvania Cancer Center and ² Philadelphia College of Pharmacy, University of the Sciences in Philadelphia, Philadelphia, Pennsylvania

Requests for reprints: Joshua H. Bilenker, Hematology-Oncology, Abramson Cancer Center, 51 North 39th Street, MAB-103, Philadelphia, PA 19104. Phone: 215-662-8632; Fax: 215-243-3269; E-mail: joshua.bilenker{at}uphs.upenn.edu.

Purpose: Preclinical evidence of synergy led to a phase I trial employing combretastatin A-4 phosphate (CA4P), a novel tubulin-binding antivascular drug, in combination with carboplatin.

Experimental Design: Based on preclinical scheduling studies, patients were treated on day 1 of a 21-day cycle. Carboplatin was given as a 30-minute i.v. infusion and CA4P was given 60 minutes later as a 10-minute infusion.

Results: Sixteen patients with solid tumors received 40 cycles of therapy at CA4P doses of 27 and 36 mg/m² together with carboplatin at area under the concentration-time curve (AUC) values of 4 and 5 mg min/mL. The dose-limiting toxicity of thrombocytopenia halted the dose escalation phase of the study. Four patients were treated at an amended dose level of CA4P of 36 mg/m² and carboplatin AUC of 4 mg min/mL although grade 3 neutropenia and thrombocytopenia were still observed. Three lines of evidence are adduced to suggest that a pharmacokinetic interaction between the drugs results in greater thrombocytopenia than anticipated: the carboplatin exposure (as AUC) was greater than predicted; the platelet nadirs were lower than predicted; and the deviation of the carboplatin exposure from predicted was proportional to the AUC of CA4, the active metabolite of CA4P. Patient benefit included six patients with stable disease lasting at least four cycles.

Conclusion: This study of CA4P and carboplatin given in combination showed dose-limiting thrombocytopenia. Pharmacokinetic/pharmacodynamic modeling permitted the inference that altered carboplatin pharmacokinetics caused the increment in platelet toxicity.

Key Words: thrombocytopenia • drug-drug interaction • renal • clearance

This article has been cited by other articles:

				T. J. Kim, M. Ravoori, C. N. Landen, A. A. Kamat, L. Y. Han, C. Lu, Y. G. Lin, W. M. Merritt, N. Jennings, W. A. Spannuth, et al. Antitumor and Antivascular Effects of AVE8062 in Ovarian Carcinoma Cancer Res., October 1, 2007; 67(19): 9337 - 9345. [Abstract] [Full Text] [PDF]

				E. L. Strevel, D. J. Ing, and L. L. Siu Molecularly Targeted Oncology Therapeutics and Prolongation of the QT Interval J. Clin. Oncol., August 1, 2007; 25(22): 3362 - 3371. [Abstract] [Full Text] [PDF]

				S.-C. J. Yeung, M. She, H. Yang, J. Pan, L. Sun, and D. Chaplin Combination Chemotherapy Including Combretastatin A4 Phosphate and Paclitaxel Is Effective against Anaplastic Thyroid Cancer in a Nude Mouse Xenograft Model J. Clin. Endocrinol. Metab., August 1, 2007; 92(8): 2902 - 2909. [Abstract] [Full Text] [PDF]

				H. W. Salmon and D. W. Siemann Effect of the Second-Generation Vascular Disrupting Agent OXi4503 on Tumor Vascularity. Clin. Cancer Res., July 1, 2006; 12(13): 4090 - 4094. [Abstract] [Full Text] [PDF]